SCHEMBL181934

SCHEMBL181934

O=C(O)c1cccc(C(=O)OCc2ccccc2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.73
KMT2A Q03164 3/20 0.73
SLC6A2 P23975 1/20 0.73
SLC6A3 Q01959 1/20 0.73
RAB9A P51151 5/20 0.63
NPC1 O15118 4/20 0.63
LMNA P02545 4/20 0.62
NR4A2 P43354 1/20 0.61
ALDH1A1 P00352 5/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPT P10636 2/20 0.57
HTT P42858 1/20 0.54
HPGD P15428 1/20 0.54
FOLH1 Q04609 1/20 0.51
MEN1 O00255 1/20 0.51
JMJD6 Q6NYC1 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL312910 0.95 TDP1 (0.81) TDP1KMT2ASLC6A2SLC6A3RAB9A
SCHEMBL11985700 0.90 TDP1 (0.69) TDP1KMT2ASLC6A2SLC6A3RAB9A
SCHEMBL312211 0.89 KMT2A (0.72) TDP1KMT2ASLC6A2SLC6A3RAB9A
SCHEMBL9266925 0.89 KMT2A (0.72) TDP1KMT2ASLC6A2SLC6A3RAB9A
SCHEMBL29079463 0.89 ALDH1A1 (0.70) TDP1KMT2ASLC6A2SLC6A3RAB9A
Benzyl Benzoate SCHEMBL8359694 0.87 KMT2A (0.89) TDP1KMT2ASLC6A2SLC6A3RAB9A
SCHEMBL27510637 0.87 LMNA (0.56) TDP1KMT2ASLC6A2SLC6A3RAB9A
SCHEMBL6282770 0.87 KMT2A (0.81) TDP1KMT2ASLC6A2SLC6A3RAB9A
SCHEMBL15534582 0.87 RAB9A (0.72) TDP1KMT2ASLC6A2SLC6A3RAB9A
SCHEMBL6001946 0.87 KMT2A (0.64) TDP1KMT2ASLC6A2SLC6A3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025109097-A2 NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF HEIDELBERG PHARMA RESEARCH GMBH (DE) 2025-05-30 WO disclosed
US-20250171419-A1 NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF HEIDELBERG PHARMA RESEARCH GMBH (DE) 2025-05-29 US disclosed
EP-3395814-B1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORP (US) 2022-04-06 EP disclosed
US-20210347756-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION 2021-11-11 US disclosed
US-10875837-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2020-12-29 US disclosed
US-20200109127-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR BLUEPRINT MEDICINES CORPORATION (US) 2020-04-09 US disclosed
US-10221154-B2 Inhibitors of the fibroblast growth factor receptor BLUEPRINT MEDICINES CORPORATION (US) 2019-03-05 US disclosed
US-9873613-B2 Nano or macro material functionalization and self assembled construction mediated by tris(trimethylsilyl)silane FUNCTIONALIZE, INC. (US) 2018-01-23 US disclosed
US-20150274674-A1 PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES PTC THERAPEUTICS, INC. (US) 2015-10-01 US disclosed
US-9096565-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2015-08-04 US disclosed
WO-1994019320-A1 AROMATIC COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE IN THERAPY MERCK SHARP & DOHME LIMITED (GB) 1994-09-01 WO disclosed
US-5003030-A Thermoplastic wholly aromatic copolyimide ester and process for producing the same IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1991-03-26 US disclosed
EP-0342652-A2 Thermoplastic wholly aromatic copolyimide ester and process for producing the same IDEMITSU PETROCHEMICAL CO. LTD. (JP) 1989-11-23 EP disclosed
EP-0055275-B1 POLYARYLENE SULPHIDE COMPOSITIONS THE GLACIER METAL COMPANY LIMITED (GB) 1985-11-27 EP disclosed
EP-0055273-B1 POLYARYLENE SULPHIDE COMPOSITIONS THE GLACIER METAL COMPANY LIMITED (GB) 1985-11-27 EP disclosed
EP-0055723-B1 METHOD OF APPLYING A COATING OF POLYARYLENE SULPHIDE TO A COOKING UTENSIL THE GLACIER METAL COMPANY LIMITED (GB) 1984-12-12 EP disclosed
US-4457924-A PENICILLINS, OXAPENICILLINS, BETA-LACTAMASE INHIBITORS PFIZER, INC. (US) 1984-07-03 US disclosed
US-4421795-A Method of applying a coating of polyarylene sulphide to a cooking utensil THE GLACIER METAL COMPANY LIMITED (GB) 1983-12-20 US disclosed
US-4405740-A Polyarylene sulphide compositions THE GLACIER METAL COMPANY LIMITED (GB) 1983-09-20 US disclosed
US-4383069-A Polyarylene sulphide compositions THE GLACIER METAL COMPANY LIMITED (GB) 1983-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109127-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 TDP1 2360/4885KMT2A 3129/4885SLC6A2 4771/4885
US-20210347756-A1 INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR FGFR4, FGFR1, FGFR2 TDP1 2360/4885KMT2A 3129/4885SLC6A2 4771/4885
US-10875837-B2 Inhibitors of the fibroblast growth factor receptor FGFR4, FGFR1, FGFR2 TDP1 2360/4885KMT2A 3129/4885SLC6A2 4771/4885
US-20150274674-A1 PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES UPF1, RNMT, VHL TDP1 189/4885KMT2A 1501/4885SLC6A2 4607/4885
US-20250171419-A1 NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF NAMPT, NAPRT, NNMT TDP1 2183/4885KMT2A 374/4885SLC6A2 237/4885
US-10221154-B2 Inhibitors of the fibroblast growth factor receptor FGFR4, FGFR1, FGFR2 TDP1 2360/4885KMT2A 3129/4885SLC6A2 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.